- Home
- LAB vs HQL Comparison
LAB vs HQL Comparison
Compare LAB & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAB
- HQL
- Stock Information
- Founded
- LAB 1999
- HQL 1992
- Country
- LAB United States
- HQL United States
- Employees
- LAB N/A
- HQL N/A
- Industry
- LAB Biotechnology: Laboratory Analytical Instruments
- HQL Investment Managers
- Sector
- LAB Industrials
- HQL Finance
- Exchange
- LAB Nasdaq
- HQL Nasdaq
- Market Cap
- LAB 372.1M
- HQL 369.6M
- IPO Year
- LAB 2011
- HQL N/A
- Fundamental
- Price
- LAB $1.34
- HQL $13.13
- Analyst Decision
- LAB Buy
- HQL
- Analyst Count
- LAB 2
- HQL 0
- Target Price
- LAB $2.50
- HQL N/A
- AVG Volume (30 Days)
- LAB 2.8M
- HQL 120.9K
- Earning Date
- LAB 07-30-2025
- HQL 01-01-0001
- Dividend Yield
- LAB N/A
- HQL 11.56%
- EPS Growth
- LAB N/A
- HQL N/A
- EPS
- LAB N/A
- HQL 0.79
- Revenue
- LAB $169,687,000.00
- HQL N/A
- Revenue This Year
- LAB N/A
- HQL N/A
- Revenue Next Year
- LAB $12.18
- HQL N/A
- P/E Ratio
- LAB N/A
- HQL $17.08
- Revenue Growth
- LAB 33.86
- HQL N/A
- 52 Week Low
- LAB $0.92
- HQL $11.34
- 52 Week High
- LAB $2.41
- HQL $14.37
- Technical
- Relative Strength Index (RSI)
- LAB 58.76
- HQL 65.80
- Support Level
- LAB $1.27
- HQL $12.84
- Resistance Level
- LAB $1.41
- HQL $13.11
- Average True Range (ATR)
- LAB 0.11
- HQL 0.19
- MACD
- LAB 0.01
- HQL 0.04
- Stochastic Oscillator
- LAB 50.00
- HQL 98.79
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.